What it's sold for

Autoimmune conditions
Immune system regulation
Chronic infection
Longevity / immune aging

What has actually been tested

Thymalfasin
Hepatitis B, Chronic
Non-small Cell Lung Cancer
Gastric Cancer
Hepatitis C
Hepatitis C, Chronic
Liver Cirrhosis
Radiotherapy

Is it studied for what it's sold for?

Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.

Not listed Autoimmune conditions

Studied Immune system regulation

Studied Chronic infection

Not listed Longevity / immune aging

Every trial on record

Every registered human study we can find for Thymosin α1. Click any ID to read the original record — we would rather you checked us than trusted us.

Trial ID	Title	Condition	Phase	Status	Enrolled
NCT07342322	A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma	Soft Tissue Sarcoma (STS)	Phase 2	Not yet recruiting	25
NCT07382375	AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection	Aortic Aneurysm and Dissection	Not phased	Not yet recruiting	300
NCT05086614	Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer	Stage II Colorectal Cancer, Stage III Colorectal Cancer	Phase 3	Recruiting now	2500
NCT06598839	Immuno-effect of Tα1 for Stage I NSCLC	Non Small Cell Lung Cancer	Not phased	Recruiting now	40
NCT06573398	Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC	Carcinoma, Pancreatic Ductal	Phase 2	Not yet recruiting	20
NCT07103395	A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer	Lung Cancer (NSCLC)	Phase 2	Recruiting now	56
NCT06461910	Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma	Gastric Cancer, Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting now	30
NCT06552598	The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies	Cervical Cancer, Gynecologic Malignancies	Phase 1	Recruiting now	97
NCT06829355	"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"	MCRC	Phase 2	Recruiting now	52
NCT06584006	Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors	Hematological Malignancy, Lymphocytopenia	Phase 2	Recruiting now	50
NCT07103408	A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer	Small-Cell Lung Cancer (SCLC)	Phase 2	Not yet recruiting	56
NCT06821100	Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine	Vaccine Response, COVID-19 Vaccine	Phase 1	Recruiting now	75
NCT05339529	Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)	Acute Aortic Syndrome, Aortic Dissection Type a	Not phased	Recruiting now	330
NCT07675980	Thymosin-α1 for Recurrent Implantation Failure	Recurrent Implantation Faliure	Phase 3	Recruiting now	136
NCT07644897	Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma	Melanoma, Immune-related Adverse Event	Phase 2	Recruiting now	55
NCT07277439	Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma	Gastric Cancer	Phase 2	Recruiting now	48
NCT06607926	Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC	Resectable Non-Small-Cell Lung Cancer	Not phased	Not yet recruiting	40
NCT01938820	Optimized Treatment and Regression of HBV-induced Early Cirrhosis	Liver Cirrhosis	Phase 4	Completed	82
NCT03082885	The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF	Liver Failure	Not phased	Completed	120
NCT04963712	Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder	HIV-1-infection	Phase 1	Completed	20
NCT02867267	The Efficacy and Safety of Ta1 for Sepsis	Sepsis	Phase 3	Completed	1106
NCT00711620	Efficacy of Thymosin alpha1 for Severe Sepsis	Severe Sepsis	Not phased	Completed	366
NCT00082082	A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma	Carcinoma, Hepatocellular	Phase 2	Completed	—
NCT01031966	A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine	END STAGE RENAL DISEASE	Phase 2	Completed	120
NCT01178996	Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.	Chronic Hepatitis C	Phase 3	Completed	552
NCT03659578	Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer	Non-small Cell Lung Cancer	Phase 2	Completed	69
NCT02646189	Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients	Hepatitis B, Chronic	Phase 2	Completed	12
NCT02366208	Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B	Hepatitis B, Chronic	Phase 2	Completed	116
NCT04428008	Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients	COVID-19	Phase 2	Completed	189
NCT01943617	Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis	Liver Cirrhosis	Phase 4	Completed	606
NCT00039962	Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin	Hepatitis C, Hepatitis C, Chronic	Phase 3	Completed	500
NCT00001036	The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection	HIV Infections	Phase 1	Completed	12
NCT00911443	Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma	Malignant Melanoma	Phase 2	Completed	488
NCT00291616	Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B	Chronic Hepatitis B	Phase 4	Completed	52
NCT02233075	REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection	Chronic HBV Infection (HBeAg Negative)	Phase 2	Completed	12
NCT00040027	Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin	Hepatitis C, Hepatitis C, Chronic	Phase 3	Completed	500
NCT02473406	Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis	Pancreatitis, Acute Necrotizing	Phase 4	Completed	508
NCT02883595	Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis	Sepsis	Phase 4	Completed	20
NCT00197860	Dendritic Cell Based Therapy of Renal Cell Carcinoma	Advanced Renal Cell Carcinoma	Phase 2	Completed	40
NCT00580450	Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies	Hematological Malignancies	Phase 2	Status not updated	9
NCT06056804	Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer	Locally Advanced Rectal Cancer	Phase 2	Running, closed to new participants	20
NCT02542930	Abscopal Effect for Metastatic Non-small Cell Lung Cancer.	Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer	Phase 2	Withdrawn before enrolling	0 — nobody enrolled
NCT05487469	Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass	Rheumatic Heart Disease, Cardiopulmonary Bypass	Not phased	Status not updated	200
NCT02545751	SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer	Esophageal Cancer, Metastatic Esophageal Cancer	Phase 2	Status not updated	29
NCT04524169	Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain	Osteoporotic Pain	Phase 4	Status not updated	100
NCT04320238	Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff	2019 Novel Coronavirus Infection	Phase 3	Status not updated	2944
NCT04487444	Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection	Covid19	Phase 2	Stopped early	56
NCT02542137	Abscopal Effect for Metastatic Small Cell Lung Cancer	Small Cell Lung Cancer, Radiotherapy	Phase 2	Withdrawn before enrolling	0 — nobody enrolled
NCT02906150	Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type	Non-Small Cell Lung Cancer	Phase 2	Status not updated	140
NCT05790447	Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors	Advanced Solid Tumor, Refractory Tumor	Phase 2	Status not updated	60
NCT06178146	Thymosin Alpha-1 for irAE Secondary to ICIs	IrAE	Phase 4	Status not updated	40
NCT06139419	The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC	Non-small Cell Lung Cancer	Phase 2	Running, closed to new participants	114
NCT05658692	Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome	Acute Respiratory Distress Syndrome	Phase 4	Status not updated	1000
NCT00935558	Dendritic Cell Based Therapy for Breast Cancer Patients	Breast Cancer	Phase 2	Withdrawn before enrolling	0 — nobody enrolled
NCT02787447	Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy	Lung Adenocarcinoma	Phase 2	Status not updated	46
NCT02976740	SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy	Lung Cancer Metastatic	Phase 2	Status not updated	48
NCT06966687	Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)	Aortic Dissection, Aortic Dissection Aneurysm	Not phased	ENROLLING_BY_INVITATION	200
NCT02535988	Abscopal Effect for Metastatic Colorectal Cancer	Colorectal Cancer, Metastatic Colorectal Cancer	Phase 2	Withdrawn before enrolling	0 — nobody enrolled
NCT02366247	Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B	Hepatitis B, Chronic	Phase 3	Status not updated	463
NCT02906163	First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy	EGFR Mutation Positive Non Small Cell Lung Cancer	Phase 2	Status not updated	188
NCT02281266	Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection	Curable Hepatitis B Virus-Related Hepatocellular Carcinoma	Phase 4	Status not updated	360
NCT06401447	TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma	Esophageal Squamous Cell Carcinoma	Not phased	Running, closed to new participants	50
NCT03448744	Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients	Chronic Hepatitis b	Phase 4	Status not updated	240

—Read this

A trial count is not a verdict

These numbers describe how much has been formally studied in humans, not whether something works or is safe for you. A compound can be tested for one condition and sold for another — which is usually the story. This page is automated aggregation from public registries; no physician has reviewed it. Take anything here to a clinician.

Common questions about Thymosin α1

How many human trials does Thymosin α1 have?

63. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.

Is Thymosin α1 FDA approved?

No. Thymosin α1 is not approved by the FDA for any indication. Compounded or "research use only" preparations are not FDA-approved and receive no premarket review for safety, effectiveness, or manufacturing quality.

What is Thymosin α1 actually being tested for?

Registered studies cover: soft tissue sarcoma (sts), aortic aneurysm and dissection, stage ii colorectal cancer. Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.

Where does this data come from?

ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.